Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
COMPARISON 3. ARIPIPRAZOLE may leads to lower adverse effects: extrapyramidal symptoms compared with RISPERIDONE (low certainty).
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes global state: No clinically significant response (as defined by the… compared with ZIPRASIDONE (very low certainty).
1 finding from 1 review
Mental state: as · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes leaving the study early compared with ZIPRASIDONE (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · patients with schizophrenia
It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes adverse effects: weight gain compared with ZIPRASIDONE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes global state: No clinically significant response compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).
1 finding from 1 review
Mental state: as · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).
1 finding from 1 review
Quality of life: as · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes adverse effects: weight gain compared with OLANZAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · patients with schizophrenia
1 finding from 1 review